Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(9):1360–1367. doi: 10.1038/bjc.1997.230

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

E Brain 1, C Garrino 1, J L Misset 1, I G Carbonero 1, M Itzhaki 1, E Cvitkovic 1, E Goldschmidt 1, F Burki 1, C Regensberg 1, E Pappo 1, R Hagipantelli 1, M Musset 1
PMCID: PMC2228243  PMID: 9155059

Abstract

The heterogeneity of therapeutic modalities and eligibility criteria and the lack of long-term follow-up in most reports of neoadjuvant chemotherapy for breast cancer preclude us from drawing conclusions about its value in clinically relevant patient subgroups. The present study aims to identify predictive and prognostic factors in 107 non-inflammatory stage II/III breast cancer patients treated between November 1980 and October 1991 with an anthracycline-based induction regimen before locoregional surgery. Preoperative chemotherapy comprised 3-6 cycles of doxorubicin (pirarubicin after 1986), vindesine, cyclophosphamide and 5-fluorouracil. Type of subsequent surgery and adjuvant treatment were decided individually. In analysis of outcome, univariate comparisons of end points were made using the log-rank test, and significant (P < or = 0.05) pre- and post-therapeutic factors were incorporated in a Cox multivariate analysis. With a median follow-up of 81 months (range 32-164+ months), the median disease-free survival (DFS) is 90.5 months while median overall survival has not yet been reached. Cytoprognostic grade and histopathological response in both the primary and lymph nodes were independent covariates associated with locoregional relapse with or without DFS and overall survival. Eleven patients with pathological complete response remain free of disease with a 68-month median follow-up, while the 18 with residual microscopic disease on the specimen showed a 60% cumulative incidence of locoregional recurrence. Despite encouraging response rates based on clinical or radiological evaluation (87% or 70%), neither method showed any significant correlation with pathological response and failed to contribute prognostic information on patients' outcome. Pathological evaluation of antitumoral activity of primary chemotherapy remains a major source of prognostic information and might be used to select patients in need of additional adjuvant treatment.

Full text

PDF
1360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res. 1992 Apr 15;52(8):2127–2137. [PubMed] [Google Scholar]
  2. Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., Bartoli C., Coopmans de Yoldi G., Zucali R., Rilke F. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990 Oct 3;82(19):1539–1545. doi: 10.1093/jnci/82.19.1539. [DOI] [PubMed] [Google Scholar]
  3. Briffod M., Spyratos F., Tubiana-Hulin M., Pallud C., Mayras C., Filleul A., Rouëssé J. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression. Cancer. 1989 Feb 15;63(4):631–637. doi: 10.1002/1097-0142(19890215)63:4<631::aid-cncr2820630405>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  4. Chevallier B., Mignot L., Delozier T., Morvan F., Ferme C., Herait P. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Am J Clin Oncol. 1992 Oct;15(5):395–398. [PubMed] [Google Scholar]
  5. De Lena M., Zucali R., Viganotti G., Valagussa P., Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1(1):53–59. doi: 10.1007/BF00253147. [DOI] [PubMed] [Google Scholar]
  6. Feldman L. D., Hortobagyi G. N., Buzdar A. U., Ames F. C., Blumenschein G. R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May;46(5):2578–2581. [PubMed] [Google Scholar]
  7. Fisher B., Mamounas E. P. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol. 1995 Mar;13(3):537–540. doi: 10.1200/JCO.1995.13.3.537. [DOI] [PubMed] [Google Scholar]
  8. Hortobagyi G. N., Ames F. C., Buzdar A. U., Kau S. W., McNeese M. D., Paulus D., Hug V., Holmes F. A., Romsdahl M. M., Fraschini G. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988 Dec 15;62(12):2507–2516. doi: 10.1002/1097-0142(19881215)62:12<2507::aid-cncr2820621210>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  9. Jacquillat C., Weil M., Baillet F., Borel C., Auclerc G., de Maublanc M. A., Housset M., Forget G., Thill L., Soubrane C. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990 Jul 1;66(1):119–129. doi: 10.1002/1097-0142(19900701)66:1<119::aid-cncr2820660122>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  10. Lin P. P., Allison D. C., Wainstock J., Miller K. D., Dooley W. C., Friedman N., Baker R. R. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol. 1993 Aug;11(8):1536–1544. doi: 10.1200/JCO.1993.11.8.1536. [DOI] [PubMed] [Google Scholar]
  11. Maloisel F., Dufour P., Bergerat J. P., Herbrecht R., Duclos B., Boilletot A., Giron C., Jaeck D., Haennel P., Jung G. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990 Feb 15;65(4):851–855. doi: 10.1002/1097-0142(19900215)65:4<851::aid-cncr2820650403>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  12. Mansi J. L., Smith I. E., Walsh G., A'Hern R. P., Harmer C. L., Sinnett H. D., Trott P. A., Fisher C., McKinna J. A. Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol. 1989 Nov;25(11):1623–1627. doi: 10.1016/0277-5379(89)90308-8. [DOI] [PubMed] [Google Scholar]
  13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  14. Mauriac L., Durand M., Avril A., Dilhuydy J. M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991 May;2(5):347–354. doi: 10.1093/oxfordjournals.annonc.a057953. [DOI] [PubMed] [Google Scholar]
  15. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  16. Misset J. L., di Palma M., Delgado M., Plagne R., Chollet P., Fumoleau P., Le Mevel B., Belpomme D., Guerrin J., Fargeot P. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol. 1996 Apr;14(4):1136–1145. doi: 10.1200/JCO.1996.14.4.1136. [DOI] [PubMed] [Google Scholar]
  17. Rouëssé J., Friedman S., Sarrazin D., Mouriesse H., Le Chevalier T., Arriagada R., Spielmann M., Papacharalambous A., May-Levin F. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986 Dec;4(12):1765–1771. doi: 10.1200/JCO.1986.4.12.1765. [DOI] [PubMed] [Google Scholar]
  18. Schaake-Koning C., van der Linden E. H., Hart G., Engelsman E. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1759–1763. doi: 10.1016/0360-3016(85)90028-8. [DOI] [PubMed] [Google Scholar]
  19. Schnitt S. J., Connolly J. L., Harris J. R., Hellman S., Cohen R. B. Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer. 1984 Mar 1;53(5):1049–1057. doi: 10.1002/1097-0142(19840301)53:5<1049::aid-cncr2820530506>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  20. Schwartz G. F., Birchansky C. A., Komarnicky L. T., Mansfield C. M., Cantor R. I., Biermann W. A., Fellin F. M., McFarlane J. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994 Jan 15;73(2):362–369. doi: 10.1002/1097-0142(19940115)73:2<362::aid-cncr2820730221>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  21. Semiglazov V. F., Topuzov E. E., Bavli J. L., Moiseyenko V. M., Ivanova O. A., Seleznev I. K., Orlov A. A., Barash N. Y., Golubeva O. M., Chepic O. F. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994 Sep;5(7):591–595. doi: 10.1093/oxfordjournals.annonc.a058929. [DOI] [PubMed] [Google Scholar]
  22. Smith I. E., Walsh G., Jones A., Prendiville J., Johnston S., Gusterson B., Ramage F., Robertshaw H., Sacks N., Ebbs S. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995 Feb;13(2):424–429. doi: 10.1200/JCO.1995.13.2.424. [DOI] [PubMed] [Google Scholar]
  23. Swain S. M., Sorace R. A., Bagley C. S., Danforth D. N., Jr, Bader J., Wesley M. N., Steinberg S. M., Lippman M. E. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987 Jul 15;47(14):3889–3894. [PubMed] [Google Scholar]
  24. Valagussa P., Zambetti M., Bonadonna G., Zucali R., Mezzanotte G., Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat. 1990 May;15(3):137–147. doi: 10.1007/BF01806351. [DOI] [PubMed] [Google Scholar]
  25. Zucali R., Uslenghi C., Kenda R., Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976 Mar;37(3):1422–1431. doi: 10.1002/1097-0142(197603)37:3<1422::aid-cncr2820370325>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  26. de Maublanc M. A. Les données récentes de la cytoponction mammaire. Ann Pathol. 1991;11(5-6):299–308. [PubMed] [Google Scholar]
  27. van der Wall E., Rutgers E. J., Holtkamp M. J., Baars J. W., Schornagel J. H., Peterse J. L., Beijnen J. H., Rodenhuis S. Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Br J Cancer. 1996 May;73(9):1080–1085. doi: 10.1038/bjc.1996.208. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES